Evidence map›Paper›PMID 41402893›Full record

ArticleGenome medicine2025

Delineation and monitoring of the T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma.

Cameron Kerr, Shirin Soleimani, David T Mulder, Arash Nabbi, Diana Gray, Stephanie Pedersen, Valentin Sotov, Sumedha Sudhaman, Linh Nguyen, Naoto Hirano and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cameron KerrPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Shirin SoleimaniPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
David T MulderPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Arash NabbiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Diana GrayPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Stephanie PedersenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Valentin SotovPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Sumedha SudhamanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Linh NguyenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Naoto HiranoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Pamela S OhashiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Marcus O ButlerPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. marcus.butler@uhn.ca.
Trevor J PughPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. trevor.pugh@utoronto.ca.

Funding

Leukemia and Lymphoma Society SCOR program 7029-23Princess Margaret Cancer Foundation Innovation Accelerator Fund
6 · The paper itself

Abstract

backgroundAdoptive cell transfer (ACT) of tumour-infiltrating lymphocytes (TIL) is an investigational treatment for solid tumours, with preliminary results showing objective clinical responses in some metastatic melanoma patients. The ability to sequence and track the T cell repertoire throughout ACT of TILs provides a method to identify T cell repertoire features associated with patients’ benefit from ACT. Identification of response biomarkers for patients receiving ACT of TILs has been limited. Conflicting evidence is observed in biomarkers such as the number of TILs in the infusion product, with some studies suggesting a relationship with response and others not. Meanwhile, certain potential biomarkers, such as the diversity of the post-infusion peripheral repertoire, have not yet been studied.

methodsIn this study, we sought to determine 1) the efficacy of using CapTCR-seq to track TILs in serial blood draws over the course of ACT immunotherapy 2) whether peripheral T cell repertoire statistics are associated with ACT response. In this study, 9 patients with cutaneous (n = 7) or mucosal (n = 2) melanoma received TIL ACT after chemotherapeutic depletion. Hybrid-capture CapTCR-seq was conducted on pre-/post-transfer peripheral blood mononuclear cells (PBMC) and cell-free DNA.

resultsComparison between PBMC DNA, PBMC RNA, and circulating free DNA (cfDNA) repertoires demonstrated an increased presence of shared T cell clonotypes post-infusion when compared with baseline samples. Higher abundance of TIL clonotypes in the PBMC baseline and post-infusion DNA T cell repertoires and the presence of shared DNA T cell clonotypes between timepoints was seen in responders when compared with non-responders according to RECIST criteria.

conclusionsThese results demonstrate effective tracking methodologies and suggest a predictive role for baseline repertoire statistics in response to the ACT of TILs.

Indexed as

Adoptive TransferImmunotherapy, AdoptiveLymphocytes, Tumor-InfiltratingMelanomaT-LymphocytesAgedFemaleHumansMaleMiddle AgedTreatment OutcomeAdoptive cell transferT cell repertoire sequencingTumour infiltrating lymphocytes

Identifiers

PMID41402893
PMCPMC12821946

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.